White Matter Hyperintensities on Brain Magnetic Resonance Imaging in People with Epilepsy: A Hospital‐Based Study

Summary Aims We aim to explore whether people with epilepsy have increased white matter hyperintensities (WMHs). Methods Eligible patients were categorized into newly diagnosed epilepsy (NE) and chronic epilepsy (CE); the latter were subdivided to those treated with enzyme‐inducing antiepileptic dru...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:CNS neuroscience & therapeutics 2016-09, Vol.22 (9), p.758-763
Hauptverfasser: Mao, Yi‐Ting, Goh, Enid, Churilov, Leonid, McIntosh, Anne, Ren, Yi‐Fan, O'Brien, Terence J., Davis, Stephen, Dong, Qiang, Yan, Bernard, Kwan, Patrick
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Aims We aim to explore whether people with epilepsy have increased white matter hyperintensities (WMHs). Methods Eligible patients were categorized into newly diagnosed epilepsy (NE) and chronic epilepsy (CE); the latter were subdivided to those treated with enzyme‐inducing antiepileptic drugs (EIAEDs) with or without non‐enzyme‐inducing antiepileptic drugs (NEIAEDs) and those with NEIAEDs only. WMHs were measured using age‐related white matter changes (ARWMC) scale and compared between patients and healthy control group. Higher scores indicate greater WMH changes. The strengths of associations were estimated as incidence rate ratios (IRRs) with 95% confidence interval (CI). Results A total of 217 patients were included in the analysis, of whom 67 had NE, 45 had CE treated with NEIAEDs, and 105 had CE treated with EIAEDs. Age was positively associated with ARWMC score (IRR per year, 1.03; 95%CI, 1.03–1.04, P < 0.001). Compared with the healthy control group (n = 23), all patient groups had higher ARWMC score (P < 0.05). The difference was greatest in patients receiving EIAEDs (IRR, 2.13; 95%CI, 1.22–3.70, P = 0.007). Conclusions WMHs tended to be observed in people with epilepsy, especially in those treated with EIAEDs. People with epilepsy with white matter changes should be evaluated for stroke risk, particularly if they are receiving EIAEDs.
ISSN:1755-5930
1755-5949
DOI:10.1111/cns.12571